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Summary
In vaccine studies, investigators are often interested in studying effect modifiers of clinical treat-
ment efficacy by biomarker-based principal strata, which is useful for selecting biomarker study
endpoints for evaluating treatments in new trials, exploring biological mechanisms of clinical
treatment efficacy, and studying mediators of clinical treatment efficacy. However, in trials where
participants may enter the study with prior exposure therefore with variable baseline biomarker
values, clinical treatment efficacy may depend jointly on a biomarker measured at baseline and
measured at a fixed time after vaccination. Therefore, it is of interest to conduct a bivariate
effect modification analysis by biomarker-based principal strata and baseline biomarker values.
Previous methods allow this assessment if participants who have the biomarker measured at the
the fixed time point post randomization would also have the biomarker measured at baseline.
However, additional complications in study design could happen in practice. For example, in
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the Dengue correlates study, baseline biomarker values were only available from a fraction of
participants who have biomarkers measured post-randomization. How to conduct the bivariate
effect modification analysis in these studies remains an open research question. In this article,
we propose an estimated likelihood method to utilize the sub-sampled baseline biomarker in the
effect modification analysis and illustrate our method with datasets from two dengue phase 3
vaccine efficacy trials.
Key words:
1. Introduction
A common problem of interest within a randomized clinical trial is the evaluation of an inex-
pensive intermediate study endpoint, typically a biomarker, as an effect modifier of the clinical
treatment efficacy which can accelerate research to apply and develop effective treatments against
the clinical outcome. Motivated by randomized placebo-controlled vaccine efficacy trials, Gilbert
and Hudgens Gilbert and Hudgens (2008), henceforth GH, proposed a clinically relevant causal
estimand called the Causal Effect Predictiveness (CEP) surface, using the principal stratification
framework developed by Frangakis and Rubin (2002) to assess whether and how treatment effi-
cacy varies by subgroups defined by intermediate response endpoint principal strata. Procedures
were developed for contrasting clinical risks under two treatment arms conditional on the pair of
potential biomarker values under two treatment arms. The CEP surface assesses a causal effect of
vaccine because the comparison groups are selected based on principal stratification, which is not
subject to post-randomization selection bias. GH expressed the concept that studying the whole
CEP surface is important that a more useful biomarker will have wide variability in the CEP
surface thus is a strong effect modifier. Unfortunately, if no further assumptions are made, the
CEP surface can not identified by the observed data because of the missing potential outcomes.
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Follmann (2006) proposed two augmented trial design to solve the problem: baseline immuno-
genicity predictors (BIP) and closeout placebo vaccination (CPV). The BIP design uses baseline
predictor(s) to infer the unobserved potential biomarker values, while the CPV design vaccinates
placebo recipients who stay uninfected at the end of the follow-up and measures their immune re-
sponse values, which are used in place of their biomarker values under vaccine. Examples of good
baseline predictors are baseline biomarker measurements in trials where participants may enter
the study with prior exposure and biomarker measurements at baseline reflects natural immu-
nity arising from pre-trial exposure to the disease-causing pathogen. Furthermore, some baseline
predictors may modify the CEP surface and contrasting clinical risks under each treatment as-
signment may depend jointly on those baseline predictors and the biomarker values measured at
a fixed time after randomization. Therefore, it is of interest to estimate CEP in those baseline
predictors defined subgroups. For example, an common question that emerges from dengue Phase
III trials is whether it is the new biomarker response generated by the vaccine over the baseline
value or the absolute biomarker value achieved following vaccination that predicts clinical treat-
ment efficacy. Comparing the CEP surface within the baseline seropositive subgroup (defined as
baseline biomarker value equal or above detection limit) to the baseline seronegative subgroup
(defined as baseline biomarker value below detection limit) could provide important insights to
this question. Previous methods allow this assessment if baseline predictors are measured in ev-
eryone. Huang (2017) studied a three-phase sampling design in which immune response is further
measured among a subset of participants for whom the baseline predictors are available. However,
additional complications in study design could happen in practice. For example, in dengue Phase
III trials, the biomarker values at baseline were only measured in a fraction of those with the
biomarker measured at the post-randomization time point. Our goal in this manuscript is to pro-
pose methods for a bivariate treatment effect modification analysis by biomarker-based principal
strata and baseline covariates in general settings without requirements of a nested sub-sampling
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relationship between the immune response biomarker and baseline predictors, in other words,
in the presence of non-monotone missingness, applicable to both the BIP-only design and the
BIP+CPV design.
The remainder of this article is organized as follows. In Section 2, we introduce the problem
setting and propose an estimator for the CEP curve that accounts for effects of the baseline
covariates together with the vaccine-induced biomarker in the risk model. In Section 3, we evaluate
the finite-sample performance of the proposed estimator through extensive numerical studies. In
Section 4, we present an analysis of two Phase 3 dengue vaccine efficacy trials using our proposed
methods. Finally, Section 5 contains a discussion of our proposed methods, their applications in
other settings, and possible areas of future research.
2. Methods
Consider a study in which N subjects are independently and randomly selected from a given
population of interest and are randomly assigned to either placebo or vaccine at baseline (time
0). Let Z = 1 if subject is randomized to vaccine and Z = 0 if subject is randomized to placebo.
Let Q be a vector of baseline covariates used for modeling disease risk and Q can be partitioned
into two part, X and B. X denotes baseline covariates recorded for everyone at baseline such as
gender and country while B denotes baseline covariates that are only available in a subset of the
N trial participants, such as baseline biomarker measurements. Trial participants are followed
for the primary clinical endpoint for a predetermined period of time and let Y be the indicator
of clinical endpoint event during the study follow-up period. At some fixed time τ > 0 post
randomization, an immune response endpoint, S, is measured. Because S must be measured
prior to disease to evaluate its treatment effect modification, availability of S is conditional on
remaining clinical endpoint free at time τ (denoted by Y τ = 0). If clinical endpoint occurs in
the time interval [0, τ ] (Y τ = 1), then S is undefined and we set S = ∗. In a CPV component
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is incorporated in the trial design, all or a fraction of placebo recipients who remain free of the
clinical endpoint at the closeout of the trial are vaccinated and the immune response biomarker Sc
is measured at time τ after vaccination. In addition, we consider cases where S is continuous and
subject to ”limit of detection” left censoring. The observable random variable S ≡ max(S∗, c)
where c is the limit of detection and S∗ has a continuous cdf with Pr(S∗ 6 c) > 0. Similarly to
S, Sc ≡ max(S∗c , c). If B denotes the baseline biomarker measurements, then observable random
variable B ≡ max(B∗, c) where B∗ has a continuous cdf with Pr(B∗ 6 c) > 0. Let S(z),S∗(z),
Y τ (z), Y (z) be the potential outcomes if assigned treatment z, for z = 0 or 1. We consider a
general sampling framework where baseline covariates X and the clinical outcome data Y and
Y τ are measured for everyone, sampling probability of B depends on X and Z, and sampling
probability of S(1) or Sc depends on Y , X and Z.
The CEP surface is defined in terms of the clinical risks under each treatment assignment,
riskz(s1, s0) ≡ P (Y (z) = 1|S(1) = s1, S(0) = s0, Y τ (1) = Y τ (0) = 0) for z = 0, 1. It conditions
on the counterfactual pair (S(0), S(1)) which forms a principal stratification and can be considered
as an unobserved baseline characteristic of each subject. The latter condition Y τ (1) = Y τ (0) = 0
ensures that causal treatment effects on S are defined. With h(x, y) being a known contrast
function satisfying h(x, y) = 0 if and only if x = y, GH defined the CEP surface as
CEP risk(s1, s0) ≡ h(risk1(s1, s0), risk0(s1, s0)).
The marginal CEP curve, closely related to the CEP surface, is also of great value in study-
ing biomarkers as effect modifiers. It contrasts the risks averaged over the distribution of S(0):
mCEP risk(s1) ≡ h(risk1(s1), risk0(s1)), where riskz(s1) ≡ P (Y (z) = 1|S(1) = s1, Y τ (1) = Y τ (0) = 0).
A example of the marginal CEP curve is vaccine efficacy as a function of S(1), which is a causal
estimand measuring the relative reduction in infection risk conferred by randomizing to vaccine
versus placebo for different levels of S(1): V E(s1) ≡ 1− risk1(s1)risk0(s1) .
In this manuscript, we propose methods to estimate the causal estimand for bivariate treat-
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ment effect modification analysis mCEP risk(S(1), B) ≡ h(risk1(S(1), B), risk0(S(1), B), ap-
plicable to both the BIP-only design and the BIP+CPV design based on an estimated likeli-
hood approach in the presence of non-monotone missingness. Furthermore, in the special case
where B denotes the baseline biomarker values, we also derive the estimator for the baseline
seropositive mCEP curve (mCEP risk(S(1), B > c) ≡ h(risk1(S(1), B > c), risk0(S(1), B > c)))
and the baseline seronegative mCEP curve (mCEP risk(S(1), B = c) ≡ h(risk1(S(1), B =
c), risk0(S(1), B = c))).
We make the common assumptions for randomized clinical trials of SUTVA (A1), ignorable
treatment assignment (A2), and Equal early clinical risk: P (Y τ (1) = Y τ (0)) = 1 (A3). These
three assumptions reduce the number of missing potential outcomes and help with identifiability of
our estimands. They have been used and discussed in details in previously literature (Gilbert and
Hudgens (2008),Gabriel and Gilbert (2014), Huang and Gilbert (2011),Huang and others (2013)).
Henceforth, we drop the notation of Y τ (1) = Y τ (0) = 0 and tacitly assume all probabilities
condition on Y τ (1) = Y τ (0) = 0. Furthermore, we assume the risk functions have a generalized
linear model form: riskz {S(1), B,X} = g {β;S(1), B, Z,X} for some known link function g(·),
for z = 0, 1 (A4).
In order to replace the unobservable S∗(1) among placebo recipients with the closeout mea-
surement S∗c , the following two assumptions are made for the BIP+CPV design only:
(A5) Time constancy of immune response: For event-free placebo recipients, S∗(1) = S∗true+U1,
and S∗c = S
∗true+U2, for some underlying S∗true and i.i.d. measurement errors U1, U2 that
are independent of one another.
(A6) No placebo subjects event-free at closeout experience the endpoint over the next τ time-
units.
Henceforth we consolidate the notation and let S∗ be the potential outcome of S∗ under
treatment arm Z = 1, either obtained during the standard trial follow-up for vaccine recipients
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or replaced by the CPV measurements for placebo recipients. We let S ≡ max(S∗, c) and δ to
be the indicator that S is measured. In addition, if B denotes the baseline biomarker values, we
also replace a missing B with S(0) if it is available for placebo recipients based on (A3) and the
next assumption (A7):
(A7) B∗ = B∗true +U3, and S∗(0) = B∗true +U4, for some underlying B∗true and i.i.d. measure-
ment errors U3, U4 that are independent of one another.
Henceforth, if B denotes the baseline biomarker values subject to detection limit: B =
max(B∗, c), then we assume that B∗ denotes the baseline biomarker values that could potentially
being replaced by S∗(0). We let B ≡ max(B∗, c) and δB to be the indicator that B is available.
For the settings we consider in this article, {i : δi = 1} and {i : δBi = 1} do not need to hold
an inclusion relationship. In section 5, we discuss the special cases where δ = 1 implies δB = 1.
Lastly, we assume observed data Oi ≡ (Zi, Xi, δi, δiSi, δBi, δBiBi, Y τi , Yi)′, i = 1, ..., n are
independent and identically distributed (i.i.d).
2.1 Risk Model Parameters Estimation
We propose an estimated likelihood estimator based on conditional likelihood for our risk model
parameters β. Subjects with δBi = δi = 1 contribute to likelihood riskZi(Si, Bi, Xi;β)
Yi(1 −
riskZi(Si, Bi, Xi;β))
1−Yi . The likelihood contribution for subjects with δBi = 1 and δSi = 0
is obtained by integrating riskZi(·, Bi, Xi;β) over the conditional cdf FS|B,X . The contribu-
tion for subjects with δi = 1 and δBi = 0 is obtained by integrating riskZi(Si, ·, Xi;β) over
the conditional cdf FB|S,X . The contribution for subjects with δi = δBi = 0 is obtained by
integrating riskZi(·, ·, Xi;β) over the conditional cdf F (B,S)|X . Define nuisance parameter ν ≡(
FB|X , FS|B,X , F (B|S,X
)
. Then the condition likelihood is
L(β, ν) ≡
n∏
i=1
f(Yi|Zi, Xi, δBi, δi, δBiBi, δiSi)
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where
f(Y |Z,X, δB, δ, δBB, δS)
=
{
riskZ(S,B,X ;β)
Y (1− riskZ(S,B,X ;β))1−Y
}δBδ
×
{(∫
riskZ(s1, B,X ;β)dF
S|B,X(s1|B,X)
)Y
×
(
1−
∫
riskZ(s1, B,X ;β)dF
S|B,X(s1|B,X)
)1−Y}δB(1−δ)
×
{(∫
riskZ(S, b,X ;β)dF
B|S,X(b|S,X)
)Y
×
(
1−
∫
riskZ(S, b,X ;β)dF
B|S,X(b|S,X)
)1−Y}(1−δB)δ
×
{(∫ ∫
riskZ(s1, b,X ;β)dF
S|B,X(s1|b,X)dFB|X(b|X)
)Y
×
(
1−
∫ ∫
riskZ(s1, b,X ;β)dF
S|B,X(s1|b,X)dFB|X(b|X)
)1−Y}(1−δB)(1−δ)
We consider the estimated likelihood approach by Pepe and Fleming (1991) Pepe and Flem-
ing (1991) where consistent estimates of ν are obtained first and then L(β, νˆ) is maximized in
β. Here we assume FB|X and FS|B,X have particular parametric distribution. For example, we
might assume FB|X is censored normal and FS|B,X is also censored normal, with left-censoring
of values below c. Then according to Bayes’ theorem, we have f(B|S,X) = f(S|B,X)f(B|X)∫
f(S|b,X)·f(b|X)db .
We obtain the maximum likelihood estimator (MLE) for FB|X using data from all individu-
als with B measured, {i : δBi = 1}. For estimation of FS|B,X = FS|B,X,Z=1, we use data from
vaccine recipients who have both S and B measured, with inverse probability weighting (IPW)
used to account for biased sampling of S. Even if there is a CPV component in the study
design, we can not use S for placebo recipients obtained during CPV because placebo recipi-
ents who are infected at study closeout have zero probability of obtaining S thus IPW is not
applicable. The estimator of β is then derived as the maximizer of the estimated likelihood
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L(β, νˆ) and m̂CEP (S,B,X) = h(g
{
β̂;S,B, Z = 1, X
}
, g
{
β̂;S,B, Z = 0, X
}
provides an esti-
mate of bivariate treatment effect modification by S and B, adjusting for X . Standard errors
for β̂ can be estimated using a perturbation resampling technique. In essence, one can gen-
erate n random realizations of ǫ from a known distribution with mean of 1 and variance of
1 to create E ≡ {ǫi, i = 1, 2, ..., n}. Let L(ǫ)(β, νˆ(ǫ)) be a perturbed version of L(β, νˆ), where
L(ǫ)(β, ν) ≡ ∏ni=1 f(Yi|Zi, Xi, δBi, δi, δBiBi, δiSi) · ǫi and ν(ǫ) is the perturbed estimator of ν
with E being the weights. Then the perturbed estimator β(ǫ) is a maximized of L(ǫ)(β, νˆ(ǫ)). In
practice, one may obtain a variance estimator of βˆ based on the empirical variance of B realiza-
tions of β(ǫ). In our simulation and example, we use B=500.
2.2 Baseline Seropositive/Seronegative mCEP Curves
In this section, we study the special case where B denotes the baseline biomarker values sub-
ject to detection limit, c, and derive the estimator for the marginal mCEP curve (mCEP (S) ≡
h(risk1(S), risk0(S))), baseline seropositive mCEP curve (mCEP (S,B > c) ≡ h(risk1(S,B >
c), risk0(S,B > c))) and the baseline seronegative mCEP curve (mCEP (S,B = c) ≡ h(risk1(S,B =
c), risk0(S,B = c))). With some calculations, the risk functions in our estimands of interest can be
expressed as: marginal risk function riskZ(S,X) =
∫∞
c− riskZ(S, b,X)dF
B|S,X(b|S,X); seropos-
itive risk function riskZ(S,B > c,X) =
P (Y (Z)=1,B>c|S,X)
P (B>c|S,X) =
∫∞
c+
riskZ (S,b,X)dF
B|S,X(b|S,X)
P (B>c|S,X) ; and
seronegative risk function riskZ(S,B = c,X). All three risk functions can be estimated based on
βˆ and νˆ.
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We consider situations where X is categorical with D levels: x1, x2, ..., xD. Then
riskZ(S) =
D∑
j=1
riskZ(S, xj) · P (X = xj |S) (2.1)
riskZ(S,B > c) =
D∑
j=1
riskZ(S,B > c, xj) · P (X = xj |S,B > c) (2.2)
riskZ(S,B = c) =
D∑
j=1
riskZ(S,B = c, xj) · P (X = xj |S,B = c). (2.3)
We model P (X |S), P (X |S,B > c), and P (X |S,B = c) using a multinomial logistic function
with parameter γ and estimate γ by MLE. Because sampling of B and S depends on other
phase-I variables such as Y , inverse prob. weighting (IPW) (Horvitz and Thompson, 1952) can
be implemented.
Appendix provides a detailed estimation procedure of mCEP (S), mCEP (S,B > c), and
mCEP (S,B = c) for the case where FB|X is assumed censored normal, FS|B,X is assume
censored normal, and the risk functions take the form riskz {S,B,X} = g {β;S,B, Z,X} =
Φ(β0 + β1Z + β2S + β3Z · S + β4B + β5Z ·B + β6X).
A perturbation resampling method can be used to make simultaneous inference of marginal
mCEP curve, baseline seropositive mCEP curve and baseline seronegative mCEP curve. To be
specific, perturbed estimators β(ǫ) and ν(ǫ) are obtained based on E . Then the corresponding
perturbed estimators m̂CEP
(ǫ)
(S), m̂CEP
(ǫ)
(S,B > c), and m̂CEP
(ǫ)
(S,B = c) are obtained
by plugging in β(ǫ) and ν(ǫ) in equation 2.1, 2.2, and 2.3. Repeat this process B times to obtain
B realizations of m̂CEP
(ǫ)
(S), m̂CEP
(ǫ)
(S,B > c), and m̂CEP
(ǫ)
(S,B = c), and calculate
the sample standard deviations σˆmCEP (S), σˆmCEP (S,B > c), σˆmCEP (S,B = C). 100(1 − α)%
pointwise confidence intervals can be constructed as
m̂CEP (S)±Z1−α/2σˆmCEP (S)
m̂CEP (S,B > c)±Z1−α/2σˆmCEP (S,B > c)
m̂CEP (S,B = c)±Z1−α/2σˆmCEP (S,B = c).
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And 100(1− α)% simultaneous confidence bands for S ∈ ζ can be constructed as
m̂CEP (S)±Q1−ασˆmCEP (S)
m̂CEP (S,B > c)±Q′1−ασˆmCEP (S,B > c)
m̂CEP (S,B = c)±Q′′1−ασˆmCEP (S,B = c),
where Z1−α/2 is the 100(1 − α/2)th percentile of N(0, 1), Q1−α is the 100(1 − α)th percentile
of supS∈ζ
∣∣∣∣∣
√
n
{
m̂CEP
risk(ǫ)
(S)−m̂CEP(S)
}
σˆmCEP (S)
∣∣∣∣∣, and Q′1−α and Q′′1−α defined similar to Q1−α with the
mCEP estimator, mCEP perturbed estimator and standard error estimator replaced by its own
version.
Furthermore, simultaneous inference enables evaluation of the hypothesis testing ofH0:mCEP (S,B >
c) = mCEP (S,B = c) for S ∈ ζ. We first construct the simultaneous confidence band for
m̂CEP (S,B > c) − m̂CEP (S,B = c). Let σ̂(m̂CEP (S,B > c) − m̂CEP (S,B = c)) denote the
sample standard deviation of the perturbed estimates m̂CEP
(ǫ)
(S,B > c)−m̂CEP (ǫ)(S,B = c).
Let Q′′′1−α be the 100(1− α)th percentile of
supS∈ζ
∣∣∣∣∣∣∣∣
√
n
{
m̂CEP
(ǫ)
(S,B > c)− m̂CEP (ǫ)(S,B = c)−
(
m̂CEP (S,B > c)− m̂CEP (S,B = c)
)}
σ̂
(
m̂CEP (S,B > c)− m̂CEP (S,B = c)
)
∣∣∣∣∣∣∣∣ .
Subsequently, the 100(1−α)% simultaneous confidence bands for m̂CEP (S,B > c)−m̂CEP (S,B =
c), S ∈ ζ is
(lα(S), uα(S)) ≡ m̂CEP (S,B > c)−m̂CEP (S,B = c)±Q′′′1−ασ̂(m̂CEP (S,B > c)−m̂CEP (S,B = c)).
The two-sided p-value for the testing H0: mCEP (S,B > c) = mCEP (S,B = c) is defined as the
minimum of α1 and α2 that satisfy
infS∈ζuα1(S) = 0, supS∈ζ lα1(S) 6 0
supS∈ζlα2(S) = 0, infS∈ζuα2(S) > 0
.
Note that at least one of α1 and α2 always exists.
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3. Simulation Studies
Through simulation studies, we evaluate the finite-sample performance of our proposed estima-
tors. Simulation data are generated with 10,000 subjects randomized to vaccine and placebo by
a ratio of 2:1. Baseline covariate X was generated with a multinomial distribution to have four
categories, 1, 2, 3, and 4 with corresponding probabilities of 0.25, 0.25, 0.25 and 0.25. X2, X3, and
X4 are dummy variables indicating category 2, 3, or 4, respectively. Baseline biomarker values
B were generated from a normal distribution with mean of 1.38 + 0.93X2 + 1.25X3 − 0.25X4
and standard deviation of 0.86. S were generated from a normal distribution with mean of
1.5+0.5B+0.2X2−0.1X3+0.4X4 and standard deviation of 0.4, which indicates a correlation of
0.7 between S and B. Let the limit of biomarker value detection be 1. Simulated values of S and
B less than 1 were set equal to 1. We assume a probit risk model of the clinical outcome Y condi-
tional on S, B, Z, andX : P (Y = 1|S,B, Z,X) = Φ(β0+β1Z+β2S+β3Z ·S+β4B+β5Z ·B+β6X).
We set (β0, β1, β2, β3, β4, β5, β6) as (−0.50, 0.16,−0.34,−0.21,−0.25, 0, (0.24, 0.11, 0.20)) so that
the probability of infection equals 0.04 in the placebo arm and 0.02 in the vaccine arm. These
simulation parameters were chosen to reflect the characteristics of the two Phase 3 Dengue trials.
To achieve a non-monotone sampling design, 35% of study participants have B retained. For the
BIP-only design, S is set missing for all placebo recipients and retained in all cases and all sub-
jects with B measured in the vaccine arm, that is {i : Zi = 1, Yi = 1} ∪ {i : Zi = 1, δBi = 1}. For
the BIP+CPV design, 70% of event-free placebo recipients are included in the CPV component
and have S retained. Simulation results are based on 500 Monte-Carlo simulations and for each
simulation 250 perturbation iterations are generated to construct point-wise confidence intervals
and simultaneous confidence bands.
We then evaluate the finite-sample performance of our proposed estimators for the marginal
VE curve (VE (S = s1)), baseline seropositive VE curve (VE (S = s1, B > c)), and baseline seroneg-
ative VE curve (VE (S = s1, B = c)). Results are presented in Figure 1 for BIP-only design and
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Figure 2 for BIP+CPV design. The empirical coverage levels of the 95% simultaneous confidence
bands from the perturbation methods are also reported as ”simultaneous.cover” in Figure 1 and
2. They demonstrate satisfactory performance of our proposed estimators, including nominal cov-
erage probabilities of the confidence intervals given fixed s1 values and simultaneous confidence
band across all s1 values.
4. Application to the CYD14 and 15 Trials
CYD14 (CYD15) is an observer-masked, randomized controlled, multi-center, phase 3 trial in
five countries in the Asia-Pacific (Latin America) region where participants were randomized
to receive three injections at month 0, 6, and 12. The primary goal is to assess vaccine efficacy
against symptomatic, virologically confirmed dengue (VCD) occurring more than 28 days after the
third injection. CYD14 achieved 56.5% efficacy (95% CI 43.8-66.4) and CYD15 achieved 60.8%
efficacy (95% CI 52.0-68.0) in the per-protocol population. Concentrations of dengue neutralizing
antibody titers to each of the four dengue serotype strains at month 13 were measured for all VCD
cases and a subset of controls, of which only a fraction have their baseline titers measured. In this
illustration, we applied our proposed method to data pooling across CYD14 and CYD15 9-16 year
olds to assess how VE varied by Month 13 titers within baseline seropositive and seronegative
subgroups. Moodie (2017) provided the justification for pooling data across these two trial for data
analysis purpose. We let S be the average of the log10-transformed neutralizing antibody titers
to each of the four dengue serotypes at month 13 and B be the average of the log10-transformed
titers at baseline. Baseline seropositive and seronegative subgroups are defined as B > 1 and
B = 1. CYD14 and CYD15 hold a non-monotone sampling design. B is available for everyone
in the immunogenicity subset ({i : δB = 1}) and S is available for all vaccine recipients who
are either in the immunogenicity subset or are cases ({i : Zi = 1, δBi = 1} ∪ {i : Zi = 1, Yi = 1}).
These two sets do not have an inclusion relationship. X denotes participants’ age and country
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categories, and Y is the indicator of VCD that took place between month 13 and end of follow
up (month 25).
Figure 3 shows the estimated VE curve and 95% CIs and CBs based on 500 perturbation
iterations. VE curves were similar for baseline seropositive and baseline seronegative subgroups,
with estimated VE approximately 25% for vaccine recipients with no seroresponse at Month
13. For vaccine recipients with Month 13 average titers of 500 and 10,000, estimated VE was
79.3% and 97.3% for the baseline seropositive subgroup compared to 70.4% and 91.8% for the
baseline seronegative subgroup, respectively. Furthermore, we tested the null hypothesis H0: BL
seropositive VE(S) =BL seronegative VE(S) for S ∈ range of month 13 average titer in vaccinees
in the data using procedure provided in section 2.2, which gave a p-value of 0.35. This suggests
that the seropositive VE curve was not significantly different from the seronegative VE curve,
implying that it is not the new neutralization response generated by the vaccine over baseline
value that predicts VE, but rather the absolute titer achieved following vaccination. See Moodie
(2017) for the reporting of the full analysis to a clinical audience.
5. Discussion
In this article, we developed an estimated likelihood approach to evaluate the bivariate treatment
effect modification analysis by biomarker-based principal strata and baseline covariates in general
settings without requirements of a nested sub-sampling relationship between the immune response
biomarker and baseline predictors suitable to both the BIP-only design and the BIP+CPV design.
In our settings, the biomarker sampled set {i : δi = 1} and the baseline covariates sampled set
{i : δBi = 1} do not need to be a subset of the other. Dengue vaccine trials CYD14 and CYD15
are examples of this non-inclusion relationship.
Our proposed method can apply to the special case where {i : δi = 1} is a subset of {i : δBi = 1}.
An example would be a three-phase sampling design when lab-assay-based baseline covariates are
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only measured from a subset of the trial participants due to high costs of acquiring lab assay
and the vaccine-induced immune response is further measured among a subset of participants
for whom the lab-assay-based baseline covariates are available. The phase 3 Zostavax Efficacy
and Safety Trial (ZEST) adopted such a three-phase sampling design to study the effect of the
Zostavax vaccine against varicella zoster virus (VZV) (Schmader and others (2012)). Under this
sampling framework, Huang (2017) proposed a semiparametric pseudo-score estimator based on
conditional likelihood and also develop several alternative semiparametric estimated likelihood
estimators when B is discrete. One can think of our work as an extension of Huang (2017) that
our proposed method can incorporate broader sampling settings including the one in Huang
(2017) and our baseline covariate B can be either discrete or continuous, possibly subject to de-
tection limit left censoring. In general, our methods are applicable to intervention studies where
a bivariate effect modification analysis is of interest where the bivariate is a post-randomization
measurement and a baseline covariate, and measurements of one do not necessarily imply mea-
surements of the other.
6. Supplementary Material
Supplementary material is available online at http://biostatistics.oxfordjournals.org.
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Fig. 1. Average bias for our proposed estimators V̂E (S(1) = s1), V̂E (S(1) = s1, B > c) and
V̂E (S(1) = s1, B = c) and coverage probabilities of 95% perturbation Wald confidence intervals in a
BIP-only design.
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Fig. 2. Average bias for our proposed estimators V̂E (S(1) = s1), V̂E (S(1) = s1, B > c) and
V̂E (S(1) = s1, B = c) and coverage probabilities of 95% perturbation Wald confidence intervals in a
BIP+CPV design.
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Fig. 3. Estimated vaccine efficacy by average log10 titer at Month 13 with 95% pointwise confidence
intervals and simultaneous confidence bands in CYD14 and CYD15 9-16-year-olds.
